 | |
| Clinical data | |
|---|---|
| Other names | Lu-AA47070; LU AA 47070; LU-AA-47070 |
| Drug class | AdenosineA2A receptorantagonist |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C17H20F2N3O6PS |
| Molar mass | 463.39 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Lu AA47070 is aselectiveadenosineA2A receptorantagonist that was under development for the treatment ofParkinson's disease but was never marketed.[1][2][3] It has been found to reverse some of the effects ofdopamineD2 receptorantagonists likepimozide andhaloperidol, for instance tremulous jaw movements,catalepsy,locomotor suppression, and otheranti-motivational effects, in animals.[2][4][5] The drug is aprodrug ofLu AA41063.[6][7][3] It was discontinued inphase 1clinical trials because it lacked the intendedpharmacological properties in humans.[7][1] Lu AA47070 was first described by 2008.[8]
Antagonists of the A2A subtype of adenosine receptor have emerged as a leading candidate class of nondopaminergic antiparkinsonian agents (Feigin, 2003). The ability of Lu AA47070, adenosine A2A antagonist to reverse the effects of D2 receptor blockade suggests that this compound could have potential utility as a treatment for parkinsonism, and for some of the motivational symptoms of depression. In the adult male Sprague Dawley rats the tremulous jaw movements induced by subchronic administration of the DA D2 antagonist pimozide were reversed by Lu AA47070. Lu AA47070 was also able to reverse the catalepsy induced by subchronic administration of the D2 antagonist pimozide and it also reverse the locomotor suppression induced by subchronic administration of the D2 antagonist pimozide (Collins et al., 2012).
{{cite journal}}: CS1 maint: overridden setting (link) | Thispharmacology-related article is astub. You can help Wikipedia byexpanding it. |